São Paulo, June 3, 2020 – Hospital São Paulo, the university hospital at the Federal University of São Paulo (HSP/HU Unifesp), has just opened 31 ICU beds to assist severe patients infected with coronavirus. This support initiative in a crucial moment of spread of the pandemic is enabled through the coordinated effort among Arteris, BTG Pactual, Eurofarma and Península. Together, these companies managed to raise BRL 3.5 million earmarked specifically to combat COVID-19. The new beds have been open since Wednesday, June 3.

The initiative has yielded a 43% increase in the hospital’s installed capacity at the dedicated ICU for COVID patients. “We will expand from 71 beds to 102 beds, a significant increase that will earn us a more comfortable occupancy rate compared to the current momentum, in which it is close to 90%. ICU beds are known to be an important deficiency at virtually all locations treating novel coronavirus cases, representing a major bottleneck within the present scenario. This donation adds a valuable support”, highlights José Roberto Ferraro, superintendent of Hospital São Paulo.

Ferraro points out that opening new ICU beds involves a complex process and physical structure, equipment and a multidisciplinary team. “The resources invested and the speed provided by the private sector enable us, together with the university, to make this significant expansion happen in only a few days. The population is the clear winner, to whom this major effort is intended”.

In addition to the delivery of hospital equipment, such as pulmonary ventilators (popularly known as respirators), cardiac monitors and cardioverters, the companies also study a possible funding subsidy in the hiring of health professionals, such as physicians and nursing technicians.

 

About BTG Pactual  

BTG Pactual is the largest investment bank in Latin America and operates in the Investment Banking, Corporate Lending, Sales & Trading, Wealth Management and Asset Management markets. Since its creation in 1983, BTG Pactual has been managed based on the meritocratic culture of partnership, with a focus on the customer, excellence and a long-term vision. The institution has established itself as one of the most innovative in the industry, having earned several national and international awards. Currently, it has almost 3,000 employees in offices spread across Brazil, Chile, Argentina, Colombia, Peru, Mexico, United States, Portugal and England. For more information, visit http:// www.btgpactual.com

 

About Arteris   

Arteris S.A. is a leader in the toll road concession sector in Brazil, with approximately 3,400 km in operation. Through its eight concession companies, it manages highways located in the states of São Paulo, Minas Gerais, Rio de Janeiro, Santa Catarina and Paraná, an important economic and industrial axis in the country. It is responsible for the operation of five federal concession companies: Fernão Dias, Régis Bittencourt, Litoral Sul, Planalto Sul and Fluminense. It also owns the state concession companies Centrovias, Intervias and ViaPaulista in São Paulo. Arteris is controlled by Spanish Abertis and Canadian Brookfield, fostering permanent security and awareness programs and contributing to the development of the communities surrounding its operations. During the COVID-19 pandemic, the company has enhanced actions to ensure the well-being of its users and vulnerable families. Since March, through its own resources and credit lines acquired through the National Bank for Economic and Social Development (BNDES), it has allocated approximately BRL 7 million for the distribution of hygiene kits, flu vaccination, expansion of resources in hospitals, among other initiatives. Learn more at www.arteris.com.br.


About Eurofarma Group 

As the first multinational pharmaceutical company with 100% Brazilian capital, the Eurofarma Group has been operating in the health industry since its establishment in 1972, producing and marketing innovative products and services to improve people’s quality of life. Focused on generating shared value, it operates in the areas of Medical Prescription, Non-Prescription, Generic, Hospital, Oncology and Veterinary. In Brazil alone, it offers 313 products, 649 dosage forms, serves 25 medical specialties and covers 89 therapeutic classes, which represent 81% of prescriptions in the brand market.

The Eurofarma Group has own operations in 20 countries, with an industrial park in Brazil and plants in six other Latin American countries. Reported sales totaled BRL 5.6 billion in 2019 and the Group employs over 7,000 employees.